Welcome to our dedicated page for Centessa Pharmaceuticals plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
Centessa Pharmaceuticals plc (CNTA) – Form 3 Initial Statement of Beneficial Ownership
The filing discloses that Mario Alberto Accardi, President of the company’s Orexin Program, beneficially owns 216,485 ordinary shares, including 25,150 restricted share units. All holdings are reported as direct.
Accardi also holds a series of employee share options covering a total of 323,425 ordinary shares with exercise prices ranging from $3.85 to $16.90 and expirations between 2032-2035. The options vest monthly over four-year periods or upon performance goal achievement, starting on various dates from March 2022 through March 2025.
No transactions were reported; this Form 3 simply establishes the insider’s starting ownership position as of 13 June 2025.
Centessa Pharmaceuticals CEO Saurabh Saha executed significant stock transactions on June 20, 2025. The transactions involved:
- Exercised 55,000 stock options at $3.85 per share
- Subsequently sold 55,000 ordinary shares at weighted average price of $12.63 per share
- Sales were executed under a pre-established Rule 10b5-1 trading plan from May 16, 2024
Post-transactions, Saha holds 221,017 ordinary shares directly and 38,000 shares indirectly through a trust. He retains 205,000 stock options exercisable until February 2033. The options vest monthly at 1/48th rate starting March 2023. This transaction resulted in an approximate gross profit of $483,000 before taxes and fees.
Centessa Pharmaceuticals plc (CNTA) – Form 144 filing overview
An affiliate identified as Saurabh Saha has notified the SEC of an intent to sell 55,000 common shares through UBS Financial Services on or about 20 June 2025. The filing quotes an aggregate market value of $707,575.
The issuer reports 133,618,774 shares outstanding; the proposed sale therefore represents roughly 0.04 % of the float, well below Rule 144’s 1 % ceiling. The shares were obtained the same day (20 Jun 2025) via a cash exercise of stock options.
Recent trading history: the same seller executed four transactions in the past three months, disposing of a total of 165,000 shares for gross proceeds of $2.30 million on 20 Mar, 21 Apr, 22 Apr and 20 May 2025. No 10b5-1 plan date or explanatory remarks were supplied.
Investor take-away: While the volume is immaterial to Centessa’s capital structure, consecutive insider sales may attract scrutiny as a potential sentiment indicator. The filing expressly states that the seller is not aware of undisclosed material information, but it offers no context regarding the rationale for continued sales.
On 20 June 2025 Centessa Pharmaceuticals plc (ticker CNTA) held its 2025 Annual General Meeting with 124,956,837 ordinary shares represented out of 133,719,291 entitled to vote, establishing quorum.
Shareholders approved every item on the agenda:
- Director re-appointments: Arjun Goyal (116.90 m for; 0.46 m against) and Samarth Kulkarni (97.75 m for; 19.61 m against).
- Auditors: KPMG LLP re-appointed as UK statutory auditor and ratified as US independent registered public accounting firm (≈125 m for; <0.01 m against).
- Auditor remuneration: Audit Committee authorised to set fees (117.13 m for).
- FY-2024 accounts: Accounts adopted; directors confirmed no dividend for FY-2024.
- Remuneration matters: Advisory vote on 2024 directors remuneration report and approval of new remuneration policy both passed.
- Share allotment authority: Directors authorised under Companies Act s.551 to allot shares/rights up to £133,184 nominal (104.16 m for; 12.98 m against).
- Special resolution: Pre-emption rights disapplied for the same nominal amount (98.23 m for; 18.90 m against).
No broker non-votes were recorded and the filing contains no disclosures on earnings, major transactions or strategic shifts. The report is primarily routine corporate-governance in nature.